National Institute on Drug Abuse; Notice of Closed Meetings, 24823-24824 [2023-08564]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 78 / Monday, April 24, 2023 / Notices
3. Revised Instructions for Reference
Letters
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
NIH proposes to update the
instructions for reference letters with
more structure so that the resulting
letters better assist reviewers in
understanding the applicant’s strengths,
weaknesses, and potential to pursue a
productive career in biomedical science.
Writers would be instructed to respond
to four questions addressing:
1. Two to four most important
characteristics that will contribute to
applicant’s success.
2. Two to four areas of needed growth.
3. Intellectual contributions made by
the applicant during training.
4. Overall assessment of readiness and
potential.
National Institutes of Health
4. Allow an Optional Statement of
Special Circumstance
NIH recommends allowing fellowship
applicants to submit an optional
Statement of Special Circumstance to
address situations that may have
hindered the trainee’s progress, such as
harassment, the COVID–19 pandemic,
or other personal or professional
circumstances.
Additional detail on proposed
changes to the Fellowship Supplement
can be found at: https://grants.nih.gov/
policy/peer/improving-nrsa-fellowship/
reviewer-instructions.
ddrumheller on DSK120RN23PROD with NOTICES1
Submitting a Response
Comments should be submitted
electronically to the following web page
at: https://rfi.grants.nih.gov/
?s=642ed5def0356688b20e6be3.
This RFI is for planning purposes
only and should not be construed as a
policy, solicitation for applications, or
as an obligation on the part of the
Government to provide support for any
ideas identified in response to it. Please
note that the Government will not pay
for the preparation of any information
submitted or for its use of that
information.
Please do not include any proprietary,
classified, confidential, or sensitive
information in your response.
Responses will be compiled and a
content analysis will be shared publicly
after the close of the comment period.
The NIH may use information gathered
by this Notice to inform future policy
development.
Dated: April 18, 2023.
Tara A. Schwetz,
Acting Principle Deputy Director, National
Institutes of Health.
[FR Doc. 2023–08603 Filed 4–21–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:50 Apr 21, 2023
Jkt 259001
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Therapeutics Development for
Opioid Use Disorder in Patients with Cooccurring Mental Disorders (UG3/UH3).
Date: May 23, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Division of Extramural Research, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 827–
5702, sindhu.kizhakkemadathil@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developed Regulated Therapeutic and
Diagnostic Solutions for Patients Affected by
Opioid and/or Stimulants Use Disorders.
Date: June 1, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Shareen Amina Iqbal,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; BRAIN
Initiative: Brain-Behavior Quantification and
Synchronization—Transformative and
Integrative Models of Behavior at the
Organismal Level.
Date: June 5, 2023.
Time: 11:00 a.m. to 5:00 p.m.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
24823
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; BRAIN
Initiative: Brain-Behavior Quantification and
Synchronization—Transformative and
Integrative Models of Behavior at the
Organismal Level.
Date: June 7, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Functional Validation and/or
Characterization of Genes or Variants
Implicated in SUD.
Date: June 5, 2023.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Preventing Opioid Misuse and CoOccurring Conditions by Intervening on
Social Determinants (R01).
Date: June 8, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Marisa Srivareerat, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 435–1258,
marisa.srivareerat@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
E:\FR\FM\24APN1.SGM
24APN1
24824
Federal Register / Vol. 88, No. 78 / Monday, April 24, 2023 / Notices
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: April 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08564 Filed 4–21–23; 8:45 am]
BILLING CODE 4140–01–P
Contact Person: Tianhong Wang, MD,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
6707 Democracy Blvd., Bethesda, MD 20892,
(301) 435–1189, wangt3@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, National Institute of
Biomedical Imaging and Bioengineering,
National Institutes of Health.)
Dated: April 18, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08559 Filed 4–21–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting of the National
Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Diversity and
Technologies for Health Disparities RFAs
review SEP.
Date: June 2, 2023.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Dem II,
Suite 920, 6707 Democracy Blvd., Bethesda,
MD 20817 (Virtual Meeting).
Contact Person: Yoon-Young Jang, MD,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Blvd., Bethesda, MD 20817, (301)
827–3025, yoon-young.jang@nih.gov.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 NCBIB Review
E–SEP.
Date: June 21–23, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Dem II,
Suite 920, 6707 Democracy Blvd., Bethesda,
MD 20817 (Virtual Meeting).
VerDate Sep<11>2014
18:50 Apr 21, 2023
Jkt 259001
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: May 22, 2023.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Maryam Rohani, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761–6656, maryam.rohani@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
PO 00000
Frm 00074
Fmt 4703
Sfmt 9990
Dated: April 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08562 Filed 4–21–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NIDA.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(6), title 5 U.S.C., as amended for
the review, discussion, and evaluation
of individual intramural programs and
projects conducted by the National
Institute on Drug Abuse, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIDA.
Date: May 2, 2023.
Closed: 9:15 a.m. to 5:30 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institute on Drug Abuse,
NIH, Biomedical Research Center, 251
Bayview Boulevard, Baltimore, MD 21224
(Virtual Meeting).
Contact Person: Deon M. Harvey, Ph.D.,
Management Analyst, Office of the Scientific
Director, National Institute on Drug Abuse,
251 Bayview Boulevard, Room 04A314,
Baltimore, MD 21224, (443) 740–2466,
deon.harvey@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: April 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–08556 Filed 4–21–23; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\24APN1.SGM
24APN1
]]>Agencies
[Federal Register Volume 88, Number 78 (Monday, April 24, 2023)]
[Notices]
[Pages 24823-24824]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08564]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: Therapeutics Development for Opioid
Use Disorder in Patients with Co-occurring Mental Disorders (UG3/
UH3).
Date: May 23, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Division of Extramural Research, Scientific Review
Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developed Regulated Therapeutic and Diagnostic
Solutions for Patients Affected by Opioid and/or Stimulants Use
Disorders.
Date: June 1, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Shareen Amina Iqbal, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; BRAIN Initiative: Brain-Behavior Quantification and
Synchronization--Transformative and Integrative Models of Behavior
at the Organismal Level.
Date: June 5, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; BRAIN Initiative: Brain-Behavior Quantification and
Synchronization--Transformative and Integrative Models of Behavior
at the Organismal Level.
Date: June 7, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Functional Validation and/or Characterization of
Genes or Variants Implicated in SUD.
Date: June 5, 2023.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, Bethesda, MD 20892, (301)
827-4471, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: Preventing Opioid Misuse and Co-
Occurring Conditions by Intervening on Social Determinants (R01).
Date: June 8, 2023.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist
[[Page 24824]]
Development Award for Clinicians, Scientist Development Awards, and
Research Scientist Awards; 93.278, Drug Abuse National Research
Service Awards for Research Training; 93.279, Drug Abuse and
Addiction Research Programs, National Institutes of Health, HHS)
Dated: April 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-08564 Filed 4-21-23; 8:45 am]
BILLING CODE 4140-01-P
